Symptom severity and quality of life in COPD patients treated with aclidinium bromide: results of a non-interventional study

Introduction: For many COPD patients, symptoms such as dyspnea and cough are most burdensome in the morning, followed by the night. This multi-center, prospective, non-interventional study investigated quality of life (QoL) and severity of nighttime and morning symptoms in patients treated with aclidinium bromide, a novel inhaled muscarinic antagonist, in daily practice. Methods: COPD patients ≥40 years of age and newly initiated on treatment with aclidinium bromide (Eklira® Genuair®; recommended dose: 400 µg twice daily) could be included. The intensity of their nighttime and morning symptoms and the impact of…